KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Goodwill & Intangibles (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Goodwill & Intangibles for 16 consecutive years, with $4.1 billion as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Goodwill & Intangibles changed N/A year-over-year to $4.1 billion, compared with a TTM value of $4.1 billion through Jun 2025, changed N/A, and an annual FY2024 reading of $4.4 billion, down 80.42% over the prior year.
  • Goodwill & Intangibles was $4.1 billion for Q2 2025 at Teva Pharmaceutical Industries, down from $4.4 billion in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $25.1 billion in Q4 2021 and bottomed at $479.0 million in Q2 2022.
  • Average Goodwill & Intangibles over 5 years is $10.7 billion, with a median of $6.5 billion recorded in 2022.
  • The sharpest move saw Goodwill & Intangibles plummeted 94.1% in 2022, then surged 1097.91% in 2023.
  • Year by year, Goodwill & Intangibles stood at $25.1 billion in 2021, then dropped by 6.58% to $23.4 billion in 2022, then fell by 3.77% to $22.6 billion in 2023, then crashed by 80.42% to $4.4 billion in 2024, then dropped by 6.25% to $4.1 billion in 2025.
  • Business Quant data shows Goodwill & Intangibles for TEVA at $4.1 billion in Q2 2025, $4.4 billion in Q4 2024, and $22.6 billion in Q4 2023.